ReNew Announces Results for the Fourth Quarter and Full Fiscal Year: Reports Highest Ever Net Profit May 18, 2026 Net Profit jumped 2.3x during the year ended March 31, 2026 Increase in net profit driven by higher operating portfolio, lower leverage and growth in manufacturing business Commissioned 2.4GW of capacity, its highest ever, during the year ended March 31, 2026
Allianz Delivers Record Operating Profit in Strong Start to 2026 May 13, 2026 1Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512320157/en/ Total business volume at 53.0 billion euros, an internal growth of 3.5 percent1. This was driven by a strong development in Property-Casualty and Asset Management Operating profit rises 6.6 percent and reaches a record level of 4.5 billion euros Shareholders’ core net [...]
SES Delivers Robust Q1 2026 Results & Reiterates Full-Year Outlook May 12, 2026 SES S.A. announces financial results for the three months ended 31 March 2026. Q1 2026 Performance (€ million) Q1 2026 as reported (1) Q1 2025 as reported (1) ∆ At constant FX (2) Q1 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.18 1.04 1.04 Revenue 847 509 +80.5% 909 [...]
Prothena Reports First Quarter 2026 Financial Results and Business Highlights May 7, 2026 Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected full year 2026 net cash used in operating and investing actives to be $18 to $23 million (versus prior guidance $50 to $55 million) and expects to end the year with approximately $273 million (midpoint) in cash, cash equivalents and restricted cash Novo Nordisk obtained Fast Track designation from the U.S. FDA for coramitug (PRX004) for the treatment of ATTR amyloidosis with cardiomyopathy and paid Prothena a $50 million clinical milestone payment related to Phase 3 enrollment Roche presented several clinical updates supporting the potential of prasinezumab for the treatment of Parkinson’s disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) Prothena has completed the Phase 1 study for PRX019. Prothena could potentially earn a $55 million clinical milestone payment if Bristol Myers Squibb decides to advance the program; BMS decision expected by year-end 2026 Prothena initiated a share repurchase program to be conducted in 2026 for up to $100 million if deemed appropriate
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026 May 6, 2026 Compass management will host a conference call at 8:00 am ET (1:00 pm UK)
IFF Reports First Quarter 2026 Results May 5, 2026 Delivered solid top and bottom line Q1 results Progressing disciplined sale process for Food Ingredients business Reaffirms Full Year 2026 Financial Guidance
Logitech Announces Q4 and Full Fiscal Year 2026 Results May 5, 2026 Strong FY 2026 Demonstrates Strategy and Operating Principles Are Delivering
Alkermes plc Reports First Quarter 2026 Financial Results May 5, 2026 Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first quarter 2026 earnings press release and presentation, please visit the company’s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. [...]
AB InBev Reports First Quarter 2026 Results May 5, 2026 Solid top- and bottom-line performance: Revenue up by 5.8%, Beer volume growth of 1.2% and a 20.8% Underlying EPS increase
Allegion (NYSE: ALLE) Reports Q1-2026 Financial Results April 28, 2026 High-Single Digit Revenue Growth for the Enterprise; Affirming FY-2026 Organic Revenue Outlook Quarterly Financial Highlights (All comparisons are year-over-year, unless otherwise noted) Net earnings per share (EPS) of $1.59, down 7.0% compared with $1.71; Adjusted EPS of $1.80, down 3.2% compared with $1.86 Revenues of $1,033.6 million, up 9.7% on a reported basis and up 2.6% on an organic basis Operating margin of 18.9%, compared with 20.9%; Adjusted operating margin of 21.2%, compared with 22.7%